<p>Forte Biosciences, Inc. (NASDAQ:FBRX - 获取免费报告) 在一月份的空头头寸显著增长。截至 1 月 15 日，空头头寸总计为 795,862 股，比 12 月 31 日的 511,832 股增长了 55.5%。根据平均交易量 201,898 股，目前的空头头寸比率为 3.9 天。目前，公司 6.8% 的股份被做空。</p>
<p>获取 <strong>Forte Biosciences</strong> 的提醒：</p>
<h2>Forte Biosciences 股价上涨 0.2%</h2>
<p>在周五的午盘交易中，FBRX 上涨了 0.05 美元，达到了 29.27 美元。该公司交易了 215,740 股，较其平均交易量 215,521 股有所增加。Forte Biosciences 的 52 周低点为 4.90 美元，52 周高点为 35.62 美元。该公司的市值为 3.6667 亿美元，市盈率为-8.82，贝塔值为 3.22。该公司的 50 日简单移动平均线为 25.79 美元，200 日简单移动平均线为 17.04 美元。</p>
<p>Forte Biosciences (NASDAQ:FBRX - 获取免费报告) 最近在 11 月 14 日公布了其财报。该公司报告季度每股收益为 (-0.99) 美元，超出分析师一致预期的 (-1.04) 美元，超出幅度为 0.05 美元。股票研究分析师预计 Forte Biosciences 在当前年度的每股收益将为-12.12 美元。</p>
<h2>分析师设定新目标价</h2>
<p>几家券商对 FBRX 发布了报告。Chardan Capital 在 11 月 17 日的报告中重申了 “买入” 评级，并将 Forte Biosciences 的目标价设定为 61.00 美元。华尔街 Zen 在 11 月 15 日的研究报告中将 Forte Biosciences 的评级从 “持有” 下调至 “卖出”。Weiss Ratings 在 12 月 29 日的研究报告中重申了 Forte Biosciences 的 “卖出 (e+)” 评级。最后，Evercore ISI 在 11 月 25 日的研究报告中开始覆盖 Forte Biosciences，给予 “跑赢大盘” 评级和 65.00 美元的目标价。目前有三位分析师给予该股票 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 67.00 美元。</p>
<p><strong>查看我们关于 Forte Biosciences 的最新研究报告</strong></p>
<h2>机构投资者对 Forte Biosciences 的看法</h2>
<p>几家对冲基金和其他机构投资者最近买入和卖出了 FBRX 的股份。美国银行在第三季度将其在 Forte Biosciences 的持股比例提高了 5,641.8%。美国银行目前拥有 3,158 股该公司的股票，价值 47,000 美元，此前在此期间又购买了 3,103 股。Dimensional Fund Advisors LP 在第三季度收购了 Forte Biosciences 的新股份，价值约为 161,000 美元。AlphaQuest LLC 在第二季度将其在 Forte Biosciences 的持股比例提高了 300.7%。AlphaQuest LLC 目前拥有 16,897 股该公司的股票，价值 218,000 美元，此前在此期间又购买了 12,680 股。Citadel Advisors LLC 在第三季度收购了 Forte Biosciences 的新股份，价值 234,000 美元。最后，Envestnet Asset Management Inc.在第二季度收购了 Forte Biosciences 的新股份，价值约为 244,000 美元。目前 77.63% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Forte Biosciences</h2>
<p>(获取免费报告)</p>
<p>Forte Biosciences, Inc 是一家临床阶段的生物技术公司，专注于开发创新疗法，通过针对皮肤屏障和微生物组的基础生物学来恢复皮肤健康。公司总部位于加利福尼亚州圣地亚哥，Forte 利用专有平台发现和推进针对严重皮肤病的局部活性生物治疗产品和皮肤屏障疗法。</p>
<p>该公司的主要产品候选 FB-401 是一种局部活性生物治疗配方，旨在重新平衡患有特应性皮炎患者的皮肤微生物组。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Forte Biosciences 更好</li>
<li>请勿删除，请立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这四个简单步骤 “防止” 你的银行账户受到影响</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Forte Biosciences 吗？</h2>
<p>在考虑 Forte Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Forte Biosciences 并不在名单上。</p>
<p>虽然 Forte Biosciences 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

标普全球医疗股指数 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

<p>Forte Biosciences, Inc.（纳斯达克代码：FBRX）在 1 月 15 日的空头头寸显著增加，增长了 55.5%，达到 795,862 股。这一增长是从 12 月 31 日的 511,832 股增加而来，基于平均每日交易量 201,898 股，空头头寸比率为 3.9 天。目前，该公司 6.8% 的股票被做空。该股票上涨了 0.2%，报 29.27 美元，市值为 3.6667 亿美元。分析师的评级意见不一，普遍评级为 “适度买入”，平均目标价为 67.00 美元</p>

<p>Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totaling 795,862 shares, a growth of 55.5% from the December 31st total of 511,832 shares. Based on an average trading volume of 201,898 shares, the short-interest ratio is currently 3.9 days. Currently, 6.8% of the company's shares are sold short. Currently, 6.8% of the company's shares are sold short. Based on an average trading volume of 201,898 shares, the short-interest ratio is currently 3.9 days.</p>
<div class="lb-trans"><p>Forte Biosciences, Inc. (NASDAQ:FBRX - 获取免费报告) 在一月份的空头头寸显著增长。截至 1 月 15 日，空头头寸总计为 795,862 股，比 12 月 31 日的 511,832 股增长了 55.5%。根据平均交易量 201,898 股，目前的空头头寸比率为 3.9 天。目前，公司 6.8% 的股份被做空。</p>
</div><p>Get <strong>Forte Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Forte Biosciences</strong> 的提醒：</p>
</div><h2>Forte Biosciences Trading Up 0.2%</h2>
<div class="lb-trans"><h2>Forte Biosciences 股价上涨 0.2%</h2>
</div><p>FBRX traded up $0.05 during midday trading on Friday, hitting $29.27. 215,740 shares of the company traded hands, compared to its average volume of 215,521. Forte Biosciences has a 52-week low of $4.90 and a 52-week high of $35.62. The company has a market capitalization of $366.67 million, a price-to-earnings ratio of -8.82 and a beta of 3.22. The business has a 50 day simple moving average of $25.79 and a two-hundred day simple moving average of $17.04.</p>
<div class="lb-trans"><p>在周五的午盘交易中，FBRX 上涨了 0.05 美元，达到了 29.27 美元。该公司交易了 215,740 股，较其平均交易量 215,521 股有所增加。Forte Biosciences 的 52 周低点为 4.90 美元，52 周高点为 35.62 美元。该公司的市值为 3.6667 亿美元，市盈率为-8.82，贝塔值为 3.22。该公司的 50 日简单移动平均线为 25.79 美元，200 日简单移动平均线为 17.04 美元。</p>
</div><p>Forte Biosciences (NASDAQ:FBRX - Get Free Report) last announced its earnings results on Friday, November 14th. The company reported ($0.99) EPS for the quarter, beating analysts' consensus estimates of ($1.04) by $0.05. Equities research analysts anticipate that Forte Biosciences will post -12.12 earnings per share for the current year.</p>
<div class="lb-trans"><p>Forte Biosciences (NASDAQ:FBRX - 获取免费报告) 最近在 11 月 14 日公布了其财报。该公司报告季度每股收益为 (-0.99) 美元，超出分析师一致预期的 (-1.04) 美元，超出幅度为 0.05 美元。股票研究分析师预计 Forte Biosciences 在当前年度的每股收益将为-12.12 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several brokerages have issued reports on FBRX. Chardan Capital reiterated a &#34;buy&#34; rating and set a $61.00 target price on shares of Forte Biosciences in a report on Monday, November 17th. Wall Street Zen downgraded Forte Biosciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 15th. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Forte Biosciences in a research note on Monday, December 29th. Finally, Evercore ISI initiated coverage on Forte Biosciences in a research note on Tuesday, November 25th. They issued an &#34;outperform&#34; rating and a $65.00 price objective for the company. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $67.00.</p>
<div class="lb-trans"><p>几家券商对 FBRX 发布了报告。Chardan Capital 在 11 月 17 日的报告中重申了 “买入” 评级，并将 Forte Biosciences 的目标价设定为 61.00 美元。华尔街 Zen 在 11 月 15 日的研究报告中将 Forte Biosciences 的评级从 “持有” 下调至 “卖出”。Weiss Ratings 在 12 月 29 日的研究报告中重申了 Forte Biosciences 的 “卖出 (e+)” 评级。最后，Evercore ISI 在 11 月 25 日的研究报告中开始覆盖 Forte Biosciences，给予 “跑赢大盘” 评级和 65.00 美元的目标价。目前有三位分析师给予该股票 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 67.00 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Forte Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Forte Biosciences 的最新研究报告</strong></p>
</div><h2>Institutional Investors Weigh In On Forte Biosciences</h2>
<div class="lb-trans"><h2>机构投资者对 Forte Biosciences 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of FBRX. Bank of America Corp DE raised its position in shares of Forte Biosciences by 5,641.8% during the 3rd quarter. Bank of America Corp DE now owns 3,158 shares of the company's stock valued at $47,000 after buying an additional 3,103 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Forte Biosciences during the third quarter worth about $161,000. AlphaQuest LLC boosted its position in Forte Biosciences by 300.7% in the 2nd quarter. AlphaQuest LLC now owns 16,897 shares of the company's stock valued at $218,000 after buying an additional 12,680 shares during the period. Citadel Advisors LLC acquired a new position in Forte Biosciences during the 3rd quarter worth $234,000. Finally, Envestnet Asset Management Inc. acquired a new position in shares of Forte Biosciences during the second quarter worth about $244,000. 77.63% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买入和卖出了 FBRX 的股份。美国银行在第三季度将其在 Forte Biosciences 的持股比例提高了 5,641.8%。美国银行目前拥有 3,158 股该公司的股票，价值 47,000 美元，此前在此期间又购买了 3,103 股。Dimensional Fund Advisors LP 在第三季度收购了 Forte Biosciences 的新股份，价值约为 161,000 美元。AlphaQuest LLC 在第二季度将其在 Forte Biosciences 的持股比例提高了 300.7%。AlphaQuest LLC 目前拥有 16,897 股该公司的股票，价值 218,000 美元，此前在此期间又购买了 12,680 股。Citadel Advisors LLC 在第三季度收购了 Forte Biosciences 的新股份，价值 234,000 美元。最后，Envestnet Asset Management Inc.在第二季度收购了 Forte Biosciences 的新股份，价值约为 244,000 美元。目前 77.63% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Forte Biosciences</h2>
<div class="lb-trans"><h2>关于 Forte Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.</p>
<div class="lb-trans"><p>Forte Biosciences, Inc 是一家临床阶段的生物技术公司，专注于开发创新疗法，通过针对皮肤屏障和微生物组的基础生物学来恢复皮肤健康。公司总部位于加利福尼亚州圣地亚哥，Forte 利用专有平台发现和推进针对严重皮肤病的局部活性生物治疗产品和皮肤屏障疗法。</p>
</div><p>The company's lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.</p>
<div class="lb-trans"><p>该公司的主要产品候选 FB-401 是一种局部活性生物治疗配方，旨在重新平衡患有特应性皮炎患者的皮肤微生物组。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Forte Biosciences</li>
<li>Do not delete, read immediately</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Forte Biosciences 更好</li>
<li>请勿删除，请立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这四个简单步骤 “防止” 你的银行账户受到影响</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Forte Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Forte Biosciences 吗？</h2>
</div><p>Before you consider Forte Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Forte Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Forte Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Forte Biosciences 并不在名单上。</p>
</div><p>While Forte Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Forte Biosciences 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Short Interest in Forte Biosciences, Inc. (NASDAQ:FBRX) Expands By 55.5%

Market Beat

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

基因改革 ETF - ARK

Forte Biosciences

美国制药 ETF - iShares

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

医药突破 ETF - ALPS

Forte Biosciences, Inc.（纳斯达克股票代码：FBRX）的空头头寸扩大了 55.5%